PT1646389E - Derivados de pirimidina-2,4-diona utilizados como antagonistas do receptor da hormona libertadora de gonadotropina - Google Patents
Derivados de pirimidina-2,4-diona utilizados como antagonistas do receptor da hormona libertadora de gonadotropina Download PDFInfo
- Publication number
- PT1646389E PT1646389E PT04777603T PT04777603T PT1646389E PT 1646389 E PT1646389 E PT 1646389E PT 04777603 T PT04777603 T PT 04777603T PT 04777603 T PT04777603 T PT 04777603T PT 1646389 E PT1646389 E PT 1646389E
- Authority
- PT
- Portugal
- Prior art keywords
- sub
- receptor antagonists
- gonadotropin
- releasing hormone
- pyrimidine
- Prior art date
Links
- 229940127445 Gonadotropin Releasing Hormone Receptor Antagonists Drugs 0.000 title 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 1
- 102000008238 LHRH Receptors Human genes 0.000 abstract 1
- 108010021290 LHRH Receptors Proteins 0.000 abstract 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48543403P | 2003-07-07 | 2003-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1646389E true PT1646389E (pt) | 2008-12-19 |
Family
ID=34079121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT04777603T PT1646389E (pt) | 2003-07-07 | 2004-07-06 | Derivados de pirimidina-2,4-diona utilizados como antagonistas do receptor da hormona libertadora de gonadotropina |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7056927B2 (enExample) |
| EP (1) | EP1646389B1 (enExample) |
| JP (2) | JP4722844B2 (enExample) |
| KR (1) | KR101139148B1 (enExample) |
| CN (1) | CN100424078C (enExample) |
| AT (1) | ATE407679T1 (enExample) |
| AU (1) | AU2004257639B2 (enExample) |
| BR (1) | BRPI0412314B8 (enExample) |
| CA (1) | CA2531508C (enExample) |
| CY (1) | CY1108656T1 (enExample) |
| DE (1) | DE602004016516D1 (enExample) |
| DK (1) | DK1646389T3 (enExample) |
| EA (1) | EA010370B1 (enExample) |
| ES (1) | ES2314448T3 (enExample) |
| HR (1) | HRP20080646T3 (enExample) |
| IL (1) | IL172833A (enExample) |
| MX (1) | MXPA06000297A (enExample) |
| NO (1) | NO334897B1 (enExample) |
| NZ (1) | NZ544747A (enExample) |
| PL (1) | PL1646389T3 (enExample) |
| PT (1) | PT1646389E (enExample) |
| SI (1) | SI1646389T1 (enExample) |
| WO (1) | WO2005007165A1 (enExample) |
| ZA (1) | ZA200600475B (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2383954T3 (es) * | 2000-01-25 | 2012-06-27 | Neurocrine Biosciences, Inc | Antagonistas del receptor de la hormona liberadora de ganodotropina y métodos relacionados con ellos |
| JP4673847B2 (ja) * | 2003-07-07 | 2011-04-20 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法 |
| CN101229165A (zh) | 2003-07-07 | 2008-07-30 | 纽罗克里生物科学有限公司 | 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物 |
| ES2314448T3 (es) * | 2003-07-07 | 2009-03-16 | Neurocrine Biosciences, Inc. | Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de la gonadotropina. |
| CN102079743B (zh) * | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| MX2009010828A (es) | 2007-04-06 | 2009-10-29 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de gonadotropina y metodos relacionados con los mismos. |
| PE20090236A1 (es) | 2007-04-06 | 2009-03-13 | Neurocrine Biosciences Inc | Antagonistas de los receptores de la hormona liberadora de gonadotropina y procedimientos relacionados con ellos |
| US20090136465A1 (en) | 2007-09-28 | 2009-05-28 | Intrexon Corporation | Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof |
| WO2009062087A1 (en) | 2007-11-07 | 2009-05-14 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| US9034850B2 (en) | 2009-11-20 | 2015-05-19 | Sk Chemicals Co., Ltd. | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same |
| IL241595B2 (en) * | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| EP2881391A1 (en) | 2013-12-05 | 2015-06-10 | Bayer Pharma Aktiengesellschaft | Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof |
| WO2016030334A2 (en) | 2014-08-26 | 2016-03-03 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| WO2017221144A1 (en) * | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| KR20230165386A (ko) | 2016-07-21 | 2023-12-05 | 옵스에파 에스에이 | 배아 착상을 촉진하고 유산을 예방하기 위한 옥시토신 길항제 투약 레지멘 |
| KR102458763B1 (ko) | 2016-08-23 | 2022-10-26 | 스완 아날라이티쉐 인스트루멘테 아크티엔게젤샤프트 | 액체의 전기 탈이온화 장치 및 방법 |
| BR112019006228A2 (pt) | 2016-09-30 | 2019-06-18 | Myovant Sciences Gmbh | tratamento de câncer de próstata |
| JP6982621B2 (ja) | 2016-09-30 | 2021-12-17 | マイオバント サイエンシズ ゲーエムベーハー | 女性不妊の治療方法 |
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| US10821188B2 (en) | 2016-12-14 | 2020-11-03 | Purdue Research Foundation | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof |
| AU2018251951B2 (en) | 2017-04-12 | 2020-09-03 | Sandoz Ag | Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist |
| EP3388421B1 (en) | 2017-04-13 | 2019-12-04 | Sandoz AG | Acid addition salts of an orally available gonadotropin-releasing hormone receptor antagonist |
| ES2770132T3 (es) | 2017-04-13 | 2020-06-30 | Sandoz Ag | Dispersión sólida amorfa de un antagonista del receptor de la hormona liberadora de gonadotropina disponible por vía oral |
| WO2018198086A1 (en) * | 2017-04-28 | 2018-11-01 | Lupin Limited | Process for the preparation of elagolix and pharmaceutically acceptable salts thereof |
| SG11201911598WA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| WO2018224063A2 (en) * | 2017-06-08 | 2018-12-13 | Zentiva, K.S. | Solid forms of elagolix |
| MX2020001877A (es) | 2017-08-18 | 2020-09-14 | Abbvie Inc | Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis. |
| US20190054088A1 (en) * | 2017-08-18 | 2019-02-21 | Abbvie Inc. | Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis |
| US12083227B2 (en) | 2017-08-18 | 2024-09-10 | Abbvie Inc. | Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
| CN107935863A (zh) * | 2017-11-30 | 2018-04-20 | 厦门海乐景生化有限公司 | Elagolix的关键原料化合物C的合成方法 |
| WO2019112968A1 (en) | 2017-12-05 | 2019-06-13 | Peng Wang | Processes to produce elagolix |
| CN110938037A (zh) * | 2018-09-21 | 2020-03-31 | 苏州鹏旭医药科技有限公司 | 一种依拉戈利钠盐药物中间体的制备方法 |
| EP3724167A1 (en) | 2017-12-11 | 2020-10-21 | Synthon B.V. | Process for preparing elagolix |
| CN109970663B (zh) * | 2017-12-27 | 2023-04-11 | 上海科胜药物研发有限公司 | 一种制备噁拉戈利中间体的方法 |
| CN108129400B (zh) * | 2017-12-29 | 2021-10-15 | 安帝康（无锡）生物科技有限公司 | 氘代噁拉戈利衍生物及其用途 |
| BR112020021276A2 (pt) | 2018-04-19 | 2021-01-26 | Abbvie Inc. | métodos de tratamento de sangramento menstrual intenso |
| CN110669013A (zh) * | 2018-07-03 | 2020-01-10 | 江苏海悦康医药科技有限公司 | 一种噁拉戈利中间体的制备方法 |
| IL280135B2 (en) | 2018-07-23 | 2024-06-01 | Abbvie Inc | Elagolix sodium compositions and processes |
| WO2020028630A1 (en) * | 2018-08-01 | 2020-02-06 | Abbvie Inc. | Dosing regimens for elagolix |
| EP3572406A1 (en) | 2018-10-17 | 2019-11-27 | Sandoz Ag | Acid addition salt of elagolix and related compounds |
| EP3873465B1 (en) | 2018-10-29 | 2025-01-15 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| US20230067378A1 (en) | 2018-11-07 | 2023-03-02 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| CN109293634A (zh) * | 2018-12-04 | 2019-02-01 | 中国药科大学 | 恶拉戈利杂质的制备方法 |
| CN109651171A (zh) * | 2019-01-13 | 2019-04-19 | 苏州鹏旭医药科技有限公司 | 依拉戈利及其钠盐的中间体及其盐的制备方法和应用 |
| EP3911327A4 (en) | 2019-01-15 | 2022-10-26 | Lupin Inc. | DEUTERED ELAGOLIX-LIKE COMPOSITIONS AND PROCESSES |
| CN109810065B (zh) * | 2019-02-16 | 2022-07-15 | 安徽华胜医药科技有限公司 | 一种恶拉戈利的合成方法 |
| CN109651265A (zh) * | 2019-02-16 | 2019-04-19 | 安徽诺全药业有限公司 | 一种Elagolix的制备方法 |
| CN109761913A (zh) * | 2019-02-16 | 2019-05-17 | 安徽华胜医药科技有限公司 | 一种有机金属钯催化合成elagolix中间体的方法 |
| CN110041232A (zh) * | 2019-04-10 | 2019-07-23 | 丽珠集团新北江制药股份有限公司 | 一种制备GnRHR药物关键中间体化合物的方法 |
| CN109956906B (zh) * | 2019-04-19 | 2021-01-29 | 奥锐特药业股份有限公司 | 一种噁拉戈利关键中间体的制备方法 |
| WO2020240375A1 (en) * | 2019-05-24 | 2020-12-03 | Dr. Reddy’S Laboratories Limited | Improved process for the preparation of elagolix and its intermediates |
| CN110204498B (zh) * | 2019-06-14 | 2020-11-27 | 奥锐特药业股份有限公司 | 一种高效合成噁拉戈利中间体的方法 |
| CN110372608A (zh) * | 2019-07-09 | 2019-10-25 | 丽珠集团新北江制药股份有限公司 | 一种促性腺激素释放激素拮抗剂的制备方法 |
| ES2802815B2 (es) | 2019-07-12 | 2022-03-14 | Moehs Iberica Sl | Sal clorhidrato de 3-[2(r)-amino-2-feniletil]-5-(2-fluoro-3-metoxifenil)-1-[2-fluoro-6-(trifluorometil)bencil]-6-metil-1h-pirimidin-2,4(1h,3h)-diona (i) en forma solida, procedimiento para su preparacion y uso de la misma en la sintesis de elagolix |
| CN110372609B (zh) * | 2019-07-25 | 2021-04-09 | 奥锐特药业股份有限公司 | 一种噁拉戈利钠盐的纯化方法 |
| WO2021016929A1 (zh) | 2019-07-31 | 2021-02-04 | 深圳仁泰医药科技有限公司 | 恶拉戈利与乙胺嘧啶的共晶型a及其制备方法和用途 |
| US20220305017A1 (en) | 2019-08-08 | 2022-09-29 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| US20220288154A1 (en) | 2019-08-08 | 2022-09-15 | ObsEva S.A. | Gnrh antagonists for the treatment of estrogen-dependent disorders |
| CH718005B1 (it) * | 2019-09-03 | 2023-07-31 | Ind Chimica Srl | Processo per la preparazione del sale sodico dell'acido 4-[[(1R)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6 (trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2H)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo. |
| IT202000001390A1 (it) * | 2020-01-24 | 2021-07-24 | Ind Chimica Srl | Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo |
| CA3149898A1 (en) | 2019-09-03 | 2021-03-11 | Ernest Loumaye | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| IT201900015458A1 (it) * | 2019-09-03 | 2021-03-03 | Ind Chimica Srl | Processo per la preparazione del sale sodico dell’acido 4-[[(1r)-2-[5-(2-fluoro-3-metossifenil)-3-[[2-fluoro-6-(trifluorometil)fenil]metil]-3,6-diidro-4-metil-2,6-diosso-1(2h)-pirimidinil]-1-feniletil]ammino]-butanoico (elagolix sale sodico) e intermedi di detto processo |
| TWI755055B (zh) * | 2019-09-18 | 2022-02-11 | 台灣神隆股份有限公司 | 用於製備惡拉戈利鈉及其中間體的方法 |
| WO2021064561A1 (en) * | 2019-10-03 | 2021-04-08 | Neuland Laboratories Limited | An improved process for the preparation of elagolix sodium |
| CN112694445B (zh) * | 2019-10-22 | 2023-07-28 | 成都倍特药业股份有限公司 | 一种噁拉戈利钠中间体的纯化方法 |
| ES2822398B2 (es) | 2019-10-30 | 2022-03-02 | Moehs Iberica Sl | 3-((R)-2-(Amino-2-feniletil)-1-(2-fluoro-6-trifluorometilbencil)-5-yodo-6-metil-1H-pirimidin-2,4-diona o una sal de la misma, procedimiento para su preparación y su uso en la síntesis de elagolix |
| US20230072265A1 (en) * | 2019-12-27 | 2023-03-09 | Msn Laboratories Private Limited, R&D Center | An improved process for the preparation of 4-({(1 r)-2-[5-(2-fluoro-3methoxyphenyl)-3-{[2-fluoro-6-(trifluoro methyl) phenyl]methyl}-4-methyl-2,6-dioxo-3,6dihydropyrimidin-1(2 h)-yl]-1-phenylethyl}amino)butanoic acid or its pharmaceutically acceptable salts |
| CN113125575B (zh) * | 2019-12-31 | 2023-04-18 | 济南尚博生物科技有限公司 | 一种1-(2-氟-6-(三氟甲基)苄基)-6-甲基嘧啶-二酮的定量分析方法 |
| CN111116490A (zh) * | 2020-01-15 | 2020-05-08 | 奥锐特药业股份有限公司 | 一种噁拉戈利中间体水杨酸盐的制备与纯化方法 |
| CN115380122A (zh) | 2020-02-10 | 2022-11-22 | 奥布赛瓦股份公司 | 用于催产素受体拮抗剂疗法的生物标志物 |
| BR112022017681A2 (pt) | 2020-03-05 | 2022-10-18 | Abbvie Inc | Métodos de administração de elagolix |
| WO2021180862A1 (en) | 2020-03-12 | 2021-09-16 | Synthon B.V. | Pharmaceutical compositions comprising elagolix sodium |
| CN111333548B (zh) * | 2020-04-10 | 2022-04-26 | 江苏海悦康医药科技有限公司 | 1-(2-氟-6-(三氟甲基)苄基)脲的制备方法 |
| CN113527213B (zh) * | 2020-04-20 | 2023-01-03 | 上海英诺富成生物科技有限公司 | 促性激素释放激素受体拮抗剂及其用途 |
| CN113683572A (zh) * | 2020-05-18 | 2021-11-23 | 陈晓雯 | 噁拉戈利的中间体及其制备方法和应用 |
| CN113880773A (zh) * | 2020-07-02 | 2022-01-04 | 南京药石科技股份有限公司 | 一种噁拉戈利中间体的制备方法 |
| CN112457258A (zh) * | 2020-11-26 | 2021-03-09 | 诚达药业股份有限公司 | 一种噁拉戈利钠及其中间体的制备方法 |
| US20220257597A1 (en) | 2021-01-29 | 2022-08-18 | Abbvie Inc. | Methods of Administering Elagolix |
| KR102656087B1 (ko) | 2024-01-12 | 2024-04-09 | 주식회사 씨엠지 | Led 소자의 에폭시 수지 코팅층 형성 방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2213510A1 (en) | 1995-06-01 | 1996-12-05 | Takeda Chemical Industries, Ltd. | Diazepinones, their production and use |
| WO1997014697A1 (en) | 1995-10-19 | 1997-04-24 | Takeda Chemical Industries, Ltd. | Thienopyridine derivatives as gonadotropin releasing hormone antagonists |
| AU7333496A (en) | 1995-10-19 | 1997-05-07 | Takeda Chemical Industries Ltd. | Quinoline derivatives as gnrh antagonists |
| JP3092947B2 (ja) | 1995-12-14 | 2000-09-25 | メルク エンド カンパニー インコーポレーテッド | ゴナドトロピン放出ホルモン拮抗剤 |
| SK77498A3 (en) | 1995-12-14 | 1999-01-11 | Merck & Co Inc | Nonpeptide derivatives, pharmaceutical composition containing them and their use |
| CZ183998A3 (cs) * | 1995-12-14 | 1998-10-14 | Merck And Co., Inc. | Nepeptidové deriváty, antagonizující hormon, uvolňující gonadotropin |
| EP0871624A1 (en) | 1995-12-14 | 1998-10-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| WO1998055119A1 (en) | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| EP0986385A4 (en) | 1997-06-05 | 2001-05-16 | Merck & Co Inc | GONADORELIN ANTAGONISTS |
| EP0986557A4 (en) | 1997-06-05 | 2001-03-14 | Merck & Co Inc | GONADOTROPIN RELEASING HORMON ANTAGONISTS |
| JP2002502426A (ja) | 1997-06-05 | 2002-01-22 | メルク エンド カンパニー インコーポレーテッド | ゴナドトロピン放出ホルモンの拮抗薬 |
| US6313301B1 (en) | 1997-08-13 | 2001-11-06 | Takeda Chemical Industries, Ltd. | Thienopyridine derivatives, their intermediates and production thereof |
| KR20020039266A (ko) | 1999-05-14 | 2002-05-25 | 추후기재 | 고나도트로핀 방출 호르몬 수용체 길항제로서의 이미다조-및 피롤로［1,2-ａ］피리미드-4-온 |
| US20020065309A1 (en) | 1999-08-04 | 2002-05-30 | Ge Peng | Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists |
| DE60022769T2 (de) | 1999-10-15 | 2006-07-06 | Neurocrine Biosciences, Inc., San Diego | Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen |
| ES2383954T3 (es) * | 2000-01-25 | 2012-06-27 | Neurocrine Biosciences, Inc | Antagonistas del receptor de la hormona liberadora de ganodotropina y métodos relacionados con ellos |
| SE0100566D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| JP2005500352A (ja) | 2001-08-02 | 2005-01-06 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | ゴナドトロピン放出ホルモンレセプター（ＧｎＲＨ）アンタゴニストとしての１，２，４−トリアジン−３，５−ジオン |
| MXPA04000985A (es) | 2001-08-02 | 2005-02-17 | Neurocrine Biosciences Inc | Piridin-4-onas sustituidas y su uso como antagonistas del receptor de hormona de liberacion de gonadotropina. |
| JP2005500356A (ja) | 2001-08-02 | 2005-01-06 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | ゴナドトロピン放出ホルモンレセプターアンタゴニスト |
| AU2002324586B2 (en) | 2001-08-02 | 2008-04-24 | Neurocrine Biosciences, Inc. | 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| US6750350B2 (en) | 2001-08-02 | 2004-06-15 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| JP4673847B2 (ja) * | 2003-07-07 | 2011-04-20 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法 |
| ES2314448T3 (es) * | 2003-07-07 | 2009-03-16 | Neurocrine Biosciences, Inc. | Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de la gonadotropina. |
| CN101229165A (zh) * | 2003-07-07 | 2008-07-30 | 纽罗克里生物科学有限公司 | 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物 |
-
2004
- 2004-07-06 ES ES04777603T patent/ES2314448T3/es not_active Expired - Lifetime
- 2004-07-06 AT AT04777603T patent/ATE407679T1/de active
- 2004-07-06 SI SI200430940T patent/SI1646389T1/sl unknown
- 2004-07-06 US US10/885,491 patent/US7056927B2/en not_active Expired - Lifetime
- 2004-07-06 KR KR1020067000436A patent/KR101139148B1/ko not_active Expired - Lifetime
- 2004-07-06 NZ NZ544747A patent/NZ544747A/en not_active IP Right Cessation
- 2004-07-06 DE DE602004016516T patent/DE602004016516D1/de not_active Expired - Lifetime
- 2004-07-06 BR BRPI0412314A patent/BRPI0412314B8/pt not_active IP Right Cessation
- 2004-07-06 MX MXPA06000297A patent/MXPA06000297A/es active IP Right Grant
- 2004-07-06 EA EA200600190A patent/EA010370B1/ru unknown
- 2004-07-06 CA CA2531508A patent/CA2531508C/en not_active Expired - Fee Related
- 2004-07-06 EP EP04777603A patent/EP1646389B1/en not_active Expired - Lifetime
- 2004-07-06 ZA ZA200600475A patent/ZA200600475B/xx unknown
- 2004-07-06 DK DK04777603T patent/DK1646389T3/da active
- 2004-07-06 AU AU2004257639A patent/AU2004257639B2/en not_active Expired
- 2004-07-06 PL PL04777603T patent/PL1646389T3/pl unknown
- 2004-07-06 HR HR20080646T patent/HRP20080646T3/xx unknown
- 2004-07-06 WO PCT/US2004/021593 patent/WO2005007165A1/en not_active Ceased
- 2004-07-06 JP JP2006518842A patent/JP4722844B2/ja not_active Expired - Lifetime
- 2004-07-06 CN CNB2004800195023A patent/CN100424078C/zh not_active Expired - Lifetime
- 2004-07-06 PT PT04777603T patent/PT1646389E/pt unknown
-
2005
- 2005-10-14 US US11/251,085 patent/US7176211B2/en not_active Expired - Lifetime
- 2005-12-26 IL IL172833A patent/IL172833A/en active Protection Beyond IP Right Term
- 2005-12-30 NO NO20056251A patent/NO334897B1/no unknown
-
2007
- 2007-01-25 US US11/627,204 patent/US7419983B2/en not_active Expired - Lifetime
-
2008
- 2008-12-09 CY CY20081101424T patent/CY1108656T1/el unknown
-
2010
- 2010-11-29 JP JP2010265830A patent/JP5226760B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200600475B (en) | Pyrimidine-2,4-dione derivatives as gonadotripin-releasing hormone receptor antagonists | |
| IL172834A0 (en) | Pyrimidine-,2,4-dione derivatives and pharmaceutical compositions containing the same | |
| WO2001055119A3 (en) | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | |
| WO2003011293A3 (en) | Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists | |
| SI1678166T1 (sl) | Inhibitorji proteinske kinaze | |
| DE60022769D1 (de) | Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen | |
| IL142893A0 (en) | Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same | |
| HUP0301892A2 (hu) | Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| ATE557007T1 (de) | Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen | |
| ATE316078T1 (de) | 1,3,5-triazine-2,4,6-trione, herstellung und anwendungen als antagonisten der gonadotropin- freisetzenden hormonrezeptoren | |
| IL158806A0 (en) | Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists | |
| AU2001261850A1 (en) | Crf receptor antagonists and methods relating thereto | |
| ATE398131T1 (de) | Kondensierte camptothecine als antitumormittel | |
| AU2001263329A1 (en) | Crf receptor antagonists and methods relating thereto | |
| PL1684763T3 (pl) | 6-arylo-7-halogeno-imidazo[1,2-a]pirymidyny jako środki przeciwnowotworowe |